The Non-Small Cell Lung Cancer ($\text{NSCLC}$) Market is undergoing a profound shift, moving away from generalized chemotherapy regimens toward highly personalized treatment strategies, driven by the discovery of actionable molecular targets. $\text{NSCLC}$ is the most common form of lung cancer, and its high mortality rate drives intensive research into more effective therapeutic modalities.Non-Small Cell Lung Cancer Market.

The cornerstone of modern $\text{NSCLC}$ treatment is Molecular Testing and Biomarker Identification. Therapies are now guided by the presence of specific genetic alterations, such as mutations in the EGFR gene, rearrangements in $\text{ALK}$ and $\text{ROS}1$, and $\text{PD}-L1$ expression levels. The market for Targeted Therapies (e.g., small molecule inhibitors) and Immunotherapies (e.g., $\text{PD}-1/\text{PD}-L1$ checkpoint inhibitors) is expanding rapidly, offering improved survival rates and quality of life for patients with these specific drivers. The necessity for routine comprehensive genomic profiling to match patients to the correct novel therapy is fundamentally driving diagnostic advancements and therapeutic development across the